4-iodo-2-(methylsulfonyl)pyridine | 1193244-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-iodo-2-(methylsulfonyl)pyridine
• 英文别名: 4-iodo-2-methylsulfonylpyridine
• CAS: 1193244-95-9
• 化学式: C₆H₆INO₂S
• 分子量: 283.09
• InChiKey: CLEZFMGDHPGYJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-iodo-2-(methylsulfonyl)pyridine 、 2-氯-4-吡啶硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 2-chloro-2'-(methylsulfonyl)-4,4'-bipyridine
  参考文献：
  名称：

  [EN] PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DU PNICTOGÈNE ET LEUR UTILISATION

  摘要：

  Disclosed are pnictogen-containing heterocyclic compounds of Formula (I). Each of R1, the heterocyclic ring H, A+, LG, and X‾ is defined herein. Also provided are methods of modifying a substrate using such a compound, conjugated biomolecules thus modified, and pharmaceutical compositions containing one of the conjugated biomolecules.

  公开号：

  WO2023191953A1
• 作为产物：
  描述：

  4-iodo-2-(methylthio)pyridine 在 sodium tungstate (VI) dihydrate 、 双氧水 作用下， 以 水 、 乙酸乙酯 为溶剂， 以82 %的产率得到4-iodo-2-(methylsulfonyl)pyridine
  参考文献：
  名称：

  [EN] PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DU PNICTOGÈNE ET LEUR UTILISATION

  摘要：

  Disclosed are pnictogen-containing heterocyclic compounds of Formula (I). Each of R1, the heterocyclic ring H, A+, LG, and X‾ is defined herein. Also provided are methods of modifying a substrate using such a compound, conjugated biomolecules thus modified, and pharmaceutical compositions containing one of the conjugated biomolecules.

  公开号：

  WO2023191953A1

文献信息

• Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1
  申请人：Claremon David A.

  公开号：US20110263584A1

  公开（公告）日：2011-10-27

  This invention relates to novel compounds of the Formula I, Ik, Iq 1-21 , Ir 1-21 , Is 1-21 , It 1-7 , pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及一种新型化合物I、Ik、Iq1-21、Ir1-21、Is1-21、It1-7，其药学上可接受的盐以及其制备的药物组合物。该化合物可用于治疗与哺乳动物中11β-HSD1的调节或抑制有关的疾病。本发明还涉及该新型化合物的药物组合物以及它们在细胞中降低或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP2291371B1

  公开（公告）日：2015-06-10
• US8569292B2
  申请人：——

  公开号：US8569292B2

  公开（公告）日：2013-10-29
• [EN] CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1<br/>[FR] INHIBITEURS CYCLIQUES DE LA 11-BÊTA-HYDROXYSTÉROÏDE DÉHYDROGÉNASE 1
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2009134392A1

  公开（公告）日：2009-11-05

  This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
• [EN] PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DU PNICTOGÈNE ET LEUR UTILISATION
  申请人：[en]UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES

  公开号：WO2023191953A1

  公开（公告）日：2023-10-05

  Disclosed are pnictogen-containing heterocyclic compounds of Formula (I). Each of R1, the heterocyclic ring H, A+, LG, and X‾ is defined herein. Also provided are methods of modifying a substrate using such a compound, conjugated biomolecules thus modified, and pharmaceutical compositions containing one of the conjugated biomolecules.